Graham Lumsden, chief executive of PLC () says the company “accomplished a lot” last year, leaving the company “in a very strong position now”.
So much so, the company is in the market for new antibiotics to add to its pipeline after making significant progress with iclaprim, its next-generation drug targeting hard-to-treat infections.
Lumsden also says the company should be ready to list on the Nasdaq market this year, with Motif already in negotiations with banks, and he adds that there are signs that markets are “starting to become a little bit more sensible” with the biotech index up around 26% so far this year.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Motif Bio PLC named herein, including the promotion by the Company of Motif Bio PLC in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE